Center volume and hereditary hemorrhagic telangiectasia June 01, 2017 Overview Show transcript Overview Vivek N. Iyer, M.D., with Pulmonary and Critical Care Medicine at Mayo Clinic in Rochester, Minnesota, discusses a study of patients with the rare disease hereditary hemorrhagic telangiectasia. Study outcomes confirm that patients with hereditary hemorrhagic telangiectasia who were hospitalized at high-volume treatment centers had better outcomes, with lower in-hospital mortality and higher home discharge rates. Read Effect of center volume on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia in the October 2016 issue of Mayo Clinic Proceedings. Share Doximity Facebook LinkedIn Twitter Print details Related ContentArticleMayo Clinic Pulmonary and Critical Care Medicine's commitment to clinical practice excellence, education enhancement and research advancement VID-20434570 Medical Professionals Center Volume & Hereditary Hemorrhagic Telangiectasia